Skip to main content

Beneficial ownership — 13D / 13G

87,339 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.

Reporting person Issuer Schedule % of class Filed
Anapass, Inc. GCTS GCT Semiconductor Holding, Inc. 13G/A 17.6% 2y
Vida Ventures, LLC KYTX Kyverna Therapeutics, Inc. 13D 11.1% 2y
SIT INVESTMENT ASSOCIATES INC FINS Angel Oak Financial Strategies Income Term Trust 13G/A 10.12% 2y
F9 Investments, LLC (Single Member LLC with Thomas D. Sullivan Single Member) LL LL Flooring Holdings, Inc. 13D/A 8.8% 2y
Robert Davidow ATXI Avenue Therapeutics, Inc. 13G/A 2.9% 2y
Board of Directors of MetLife, Inc., as an entity MET Metlife Inc 13D/A 16.2% 2y
Crestview Partners III GP, L.P. WOW WideOpenWest, Inc. Common Stock 13D/A 38% 2y
River Road Asset Management, LLC PLUS Eplus Inc 13G/A 4.9% 2y
Starboard Value LP GDDY GoDaddy Inc. 13D/A 4.8% 2y
Saba Capital Management, L.P. LGI Lazard Global Total Return & Income Fund Inc 13D/A 7.72% 2y
River Road Asset Management, LLC RPC Ridgepost Capital, Inc. 13G 11.2% 2y
GILEAD SCIENCES, INC. LKFT Lakefront Biotherapeutics NV 13D/A 29.9% 2y
IndexIQ Advisors LLC CWI Spdr Index Shares Funds 13G/A 0% 2y
GK Investor LLC GNK Genco Shipping & Trading Ltd 13D/A 5.5% 2y
MILLENNIUM MANAGEMENT LLC GDRX GoodRx Holdings, Inc. 13G 5.1% 2y
Barak Matalon OR ABOVE PERSON (ENTITIES ONLY) NGMS NeoGames S.A. Ordinary Shares 13D/A 0% 2y
D. E. Shaw & Co., L.P. IBTA Ibotta, Inc. 13G 9.6% 2y
RA CAPITAL MANAGEMENT, L.P. ZURA Zura Bio Ltd 13G 5.1% 2y
Venrock Healthcare Capital Partners III, L.P. ZURA Zura Bio Ltd 13G 9.99% 2y
Paradigm Biocapital Advisors LP KURA Kura Oncology, Inc. 13G 5.1% 2y
Joel Charles Sklar ACFN Acorn Energy, Inc. 13G 5.7% 2y
Kessler Judd S CLDI Calidi Biotherapeutics, Inc. 13D 5% 2y
De Lisle Partners LLP FRD Friedman Industries Inc 13G 5.8% 2y
IndexIQ Advisors LLC UUP Invesco DB US Dollar Index Bullish Fund 13G/A 10.5% 2y
GAMCO INVESTORS, INC. ET AL CMT Core Molding Technologies Inc 13D/A 4.45% 2y
Brookstone Capital Management AAPR Innovator ETFs Trust 13G/A 6.61% 2y
Brown-Forman Corporation NAPA The Duckhorn Portfolio, Inc. 13D 21.5% 2y
GAMCO INVESTORS, INC. ET AL STRT Strattec Security Corp 13D/A 18.22% 2y
Brookstone Capital Management AAPR Innovator ETFs Trust 13G/A 3.53% 2y
Saba Capital Management, L.P. CXH Mfs Investment Grade Municipal Trust 13D/A 3.85% 2y
Imperial Petroleum Inc. CISS C3is Inc. 13D/A 67.2% 2y
Brookstone Capital Management AAPR Innovator ETFs Trust 13G 11.82% 2y
Adage Capital Management, L.P. EYPT EyePoint, Inc. 13G/A 9.9% 2y
PERCEPTIVE ADVISORS LLC TRIB Trinity Biotech PLC 13D/A 26.8% 2y
Vivo Opportunity Fund Holdings, L.P. SLNO Soleno Therapeutics Inc 13D/A 22.5% 2y
Madryn Asset Management, LP GBNH Greenbrook TMS Inc. Common Shares 13D/A 61.7% 2y
Monte M. Brem STEP StepStone Group Inc. 13D/A 47.4% 2y
Saba Capital Management, L.P. ASA ASA Gold & Precious Metals Ltd 13D/A 16.87% 2y
Braden Ferrari BTLN Brightline Interactive, Inc. 13G/A 5.4% 2y
Vikasati Partners LLC CMCAF Piermont Valley Acquisition Corp 13D 56.37% 2y
Millennium Management LLC MYGN Myriad Genetics Inc 13G 5% 2y
Rock Springs Capital Management LP TVTX Travere Therapeutics, Inc. 13G 5.79% 2y
Phoenix Financial Ltd. RMTHF Magic Software Enterprises Ltd 13G 5.01% 2y
BARD ASSOCIATES INC LGL Lgl Group Inc 13G/A 9.8% 2y
Transform Wealth, LLC AAPR Innovator ETFs Trust 13G/A 0% 2y
J. Mariner Kemper UMBF Umb Financial Corp 13D/A 8.4% 2y
Shawn Devlin BMRC Bank of Marin Bancorp 13D/A 3.5% 2y
GIC Private Ltd UXIN Uxin Ltd 13G/A 6.85% 2y
Harrow, Inc. ETON Eton Pharmaceuticals, Inc. 13D/A 0% 2y
Legion Partners Asset Management, LLC NNBR Nn Inc 13D/A 9.9% 2y